At first glance, up-regulation of GMFB might compromise the neuroinflammatory state; however, according to our validated in vivo results, we can confirm that ERK-NF-κB orchestrates a decrease in pro-inflammatory NF-kB target genes in AD progression in response to G9a inhibition. This evidence concerns the gene NFKB1 and Alzheimer disease.